Traders Sell Johnson & Johnson (JNJ) on Strength (JNJ)
Traders sold shares of Johnson & Johnson (NYSE:JNJ) on strength during trading hours on Thursday. $92.14 million flowed into the stock on the tick-up and $122.96 million flowed out of the stock on the tick-down, for a money net flow of $30.82 million out of the stock. Of all equities tracked, Johnson & Johnson had the 0th highest net out-flow for the day. Johnson & Johnson traded up $1.52 for the day and closed at $132.19
A number of equities research analysts have recently issued reports on the company. UBS AG reaffirmed a “buy” rating and set a $136.00 target price on shares of Johnson & Johnson in a research report on Monday, May 15th. Vetr raised Johnson & Johnson from a “hold” rating to a “buy” rating and set a $132.33 target price on the stock in a research report on Thursday, May 18th. J P Morgan Chase & Co boosted their target price on Johnson & Johnson from $140.00 to $148.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 16th. Stifel Nicolaus reaffirmed a “hold” rating and set a $128.00 target price (up from $124.00) on shares of Johnson & Johnson in a research report on Thursday, May 18th. Finally, BidaskClub raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Saturday, June 17th. Three equities research analysts have rated the stock with a sell rating, nine have given a hold rating and ten have given a buy rating to the stock. Johnson & Johnson has an average rating of “Hold” and a consensus price target of $134.60.
The stock has a market cap of $351.55 billion, a PE ratio of 22.16 and a beta of 0.79. The company’s 50-day moving average price is $132.48 and its 200 day moving average price is $128.74.
Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Tuesday, July 18th. The company reported $1.83 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.79 by $0.04. Johnson & Johnson had a return on equity of 26.76% and a net margin of 22.52%. The firm had revenue of $18.84 billion for the quarter, compared to the consensus estimate of $18.94 billion. During the same quarter last year, the business posted $1.74 EPS. The company’s revenue for the quarter was up 1.9% on a year-over-year basis. Analysts forecast that Johnson & Johnson will post $7.18 EPS for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 12th. Shareholders of record on Tuesday, August 29th will be paid a $0.84 dividend. This represents a $3.36 annualized dividend and a dividend yield of 2.57%. The ex-dividend date is Friday, August 25th. Johnson & Johnson’s dividend payout ratio is 56.76%.
In other Johnson & Johnson news, VP Paulus Stoffels sold 102,692 shares of Johnson & Johnson stock in a transaction dated Monday, July 24th. The stock was sold at an average price of $133.14, for a total value of $13,672,412.88. Following the sale, the vice president now owns 230,342 shares of the company’s stock, valued at approximately $30,667,733.88. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Dominic J. Caruso sold 82,591 shares of Johnson & Johnson stock in a transaction dated Thursday, July 20th. The shares were sold at an average price of $136.72, for a total value of $11,291,841.52. Following the completion of the sale, the vice president now directly owns 226,693 shares in the company, valued at approximately $30,993,466.96. The disclosure for this sale can be found here. Company insiders own 0.19% of the company’s stock.
Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Harding Loevner LP acquired a new stake in shares of Johnson & Johnson in the second quarter valued at about $106,000. Lenox Wealth Advisors Inc. increased its position in shares of Johnson & Johnson by 0.7% in the first quarter. Lenox Wealth Advisors Inc. now owns 871 shares of the company’s stock valued at $108,000 after acquiring an additional 6 shares during the last quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. increased its position in shares of Johnson & Johnson by 29.9% in the second quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 870 shares of the company’s stock valued at $115,000 after acquiring an additional 200 shares during the last quarter. IHT Wealth Management LLC increased its position in shares of Johnson & Johnson by 46.4% in the second quarter. IHT Wealth Management LLC now owns 10,942 shares of the company’s stock valued at $122,000 after acquiring an additional 3,467 shares during the last quarter. Finally, Mountain Capital Investment Advisors Inc acquired a new stake in shares of Johnson & Johnson in the second quarter valued at about $124,000. 66.00% of the stock is currently owned by hedge funds and other institutional investors.
About Johnson & Johnson
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.